334-49-6

Usage

Uses

Used in Pharmaceutical Applications:
TRANS-2-DECENOIC ACID is used as a pharmaceutical agent for its weak estrogenic activity, which helps in inhibiting the binding of 17β-estradiol to estrogen receptor β. This property makes it a potential candidate for the development of treatments related to estrogen receptor β.
Used in Perfumery:
TRANS-2-DECENOIC ACID is used as a fragrance ingredient in the perfumery industry due to its peach-orange, slightly waxy aroma. Its unique scent adds a distinct and pleasant note to various perfume compositions.
Used in the Food Industry:
TRANS-2-DECENOIC ACID can be used in the food industry as a natural flavoring agent, taking advantage of its pleasant aroma to enhance the taste and smell of various food products.
Used in Cosmetics:
Due to its weak estrogenic activity, TRANS-2-DECENOIC ACID may also find applications in the cosmetics industry, potentially being used in the development of skincare products that target estrogen-related skin issues.

InChI:InChI=1S/C10H18O2/c1-2-3-4-5-6-7-8-9-10(11)12/h8-9H,2-7H2,1H3,(H,11,12)/b9-8+

Upstream product

• 124-38-9 carbon dioxide 
• 52886-17-6 (Z)-1-iodo-1-nonene 
• 61746-55-2 Hept₂CuLi 
• 74-86-2 acetylene 
• 3913-81-3 (E)-2-decenal 
• 124-13-0 Octanal 
• 141-82-2 malonic acid 
• 2497-25-8 2-decenal 
• 2623-95-2 2-bromodecanoic acid 
• 65946-59-0 (trimethylsilyl)ketene bis(trimethylsilyl) acetal 
• 631-64-1 dibromoacetic acid 
• 956830-72-1 N-[(E)-dec-2-enoyl]morpholine 
• 66-25-1 hexanal 
• 334-48-5 1-decanoic acid 

Downstream Products

• 7367-85-3 methyl (E)-dec-2-enoate 
• 334-48-5 1-decanoic acid 
• 143121-61-3 (1R,2S,5R)-(+)-menthol 2-decenoate 
• 939125-15-2 (E)-N-[2-amino-6-(benzyloxy)-5-nitrosopyrimidin-4-yl]dec-2-enamide 
• 303957-69-9 (2R)-4-acetyl-1,2-dihydro-5-hydroxy-2-(2-methylpropyl)-1-[(2E)-1-oxodec-2-enyl]-3H-pyrrol-3-one 
• 864531-14-6 2-{[3-(acetyl-benzoyloxy-amino)-propylcarbamoyl]-methyl}-N-[3-(benzoyloxy-dec-2-enoyl-amino)-propyl]-2-hydroxy-succinamic acid tert-butyl ester 
• 7367-88-6 ethyl (E)-2-decenate 
• 137089-37-3 2-(E-2-decenoylamino)ethyl cyclohexylmethyl sulfide 
• 137089-39-5 2-(E-2-decenoylamino)ethyl 2-phenylmethyl sulfide 
• 137089-38-4 2-(E-2-decenoylamino)ethyl 2-phenylethyl sulfide 
• 137089-36-2 2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide 
• 60139-03-9 methyl 6-heptyl-4-hydroxy-2-oxocyclohex-3-enecarboxylate 
• 1129972-43-5 trans-2-decenoic acid cyclohexyl ester 

Relevant academic research and scientific papers

Synthesis of (±)tetrahydromyricoidine

A total synthesis of the spermidine alkaloid (±)-tetrahydromyricoidine (6) was achieved by using two ring enlargement reactions. The difficulties experienced in the second ring enlargement step, a transamidation reaction with a medium ring sized lactam bearing two bulky groups are discussed. These were overcome by altering the reaction sequence and the transamidation reaction was successfully carried out by at first deprotection of the Boc function. spermidine alkaloids; (±)-tetrahydromyricoidine; ring enlargement.

Compound with cinnamon fragrance as well as preparation method and application thereof

The invention relates to a compound with cinnamon fragrance as well as a preparation method and application thereof. The compound has the following structural formula, wherein the structural formula can be named as 2-decenoic acid-2-(4-methoxy)-phenyl-2-butyl ester. The provided compound has the advantages of obvious cinnamon aroma, rich aroma, lasting aroma and good stability, and enriches the sources of cinnamon aroma. When the essence is prepared in different periods, the compound has consistent cinnamon aroma, so that the required aroma can be accurately mastered.

ANTI-BACTERIAL CALCIUM-DEPENDENT ANTIBIOTIC (CDA) ANALOGS AND METHODS OF TREATING BACTERIAL INFECTIONS

Provided herein are calcium-dependent antibiotics (CDAs), as a novel therapeutic target for treating bacterial infections. The present invention also relates to pharmaceutical compositions comprising such compounds, and to methods of use thereof for combating bacteria and treating bacterial infections.

Convergent Synthesis of Calcium-Dependent Antibiotic CDA3a and Analogues with Improved Antibacterial Activity via Late-Stage Serine Ligation

A convergent synthesis via the late-stage serine ligation of naturally occurring calcium-dependent antibiotic CDA3a and its analogues has been developed, which allowed us to readily synthesize the analogues with the variation on the lipid tail. Some analogues were found to show 100-500-fold higher antimicrobial activity than the natural compound CDA3a against drug resistant bacteria. This study will enhance our understanding of CDA3a and provide valuable antibacterial lead candidates for further development.

Profiling structural diversity and activity of 2-alkyl-4(1H)-quinoloneN-oxides ofPseudomonasandBurkholderia

We synthesized all major saturated and unsaturated 2-alkyl-4(1H)-quinoloneN-oxides ofPseudomonasandBurkholderia, quantified their native production levels and characterized their antibiotic activities against competingStaphylococcus aureus. We demonstrate that quinolone core methylation and position of unsaturation in the alkyl-chain dictate antibiotic potency which supports the proposed mechanism of action.

METHOD AND COMPOSITION FOR WATER TREATMENT

The invention provides a method of microbial control in water comprising adding to the water one or more bromine-based biocide(s) and cis-2-decenoic acid or a salt thereof. Compositions in the form of liquid concentrates comprising bromine-based biocides and cis-2-decenoic acid or a salt thereof are also described.

COMPOUND FOR USE AGAINST PATHOGENIC NEISSERIA AND HAEMOPHILUS SPECIES AND MORAXELLA CATARRHALIS

The present invention relates to a compound, which can be used in the prevention and treatment of infections with pathogenic Neisseria species, in particular N. gonorrhoeae and N. meningitidis (the gonococcus and the meningococcus, respectively), and other pathogenic bacteria (e.g. Haemophilus species or Moraxella catarrhalis ), and which can be used for disinfecting a substrate from said bacteria. Moreover, the present invention relates to a corresponding pharmaceutical composition comprising said compound.

Unexpected AChE inhibitory activity of (2E)α,β-unsaturated fatty acids

A small library of (E) α,β-unsaturated fatty acids was prepared, and 20 different saturated and mono-unsaturated fatty acids differing in chain length were subjected to Ellman's assays to determine their ability to act as inhibitors for AChE or BChE. While the compounds were only very weak inhibitors of BChE, seven molecules were inhibitors of AChE holding IC50 = 4.3–12.8 M with three of them as significant inhibitors of this enzyme. The results have shown trans 2-mono-unsaturated fatty acids are better inhibitors for AChE than their saturated analogs. Furthermore, the screening results indicate that the chain length is crucial for obtaining an inhibitory efficacy. The best results were obtained for (2E) eicosenoic acid (14) showing inhibition constants Ki = 1.51 ± 0.09 M and Ki′ = 7.15 ± 0.55 M. All tested compounds were mixed-type inhibitors with a dominating competitive part. Molecular modelling calculations indicate a different binding mode of active/inactive compounds for the enzymes AChE and BChE.

Enantioselective Synthesis of N?H-Free 1,5-Benzothiazepines

An enantioselective sulfa-Michael-cyclization reaction was developed for the synthesis of 1,5-benzothiazepines with versatile pharmacological activities. The reaction between 2-aminothiophenol and α,β-unsaturated pyrazoleamides gave direct access to N?H-free 1,5-benzothiazepines in the presence of a chiral N,N′-dioxide/Yb(OTf)3complex. Excellent enantioselectivities (up to 96 % ee) and high yields (up to 99 %) were obtained for a broad range of substrates under mild reaction conditions. This method provided a facile approach to the antidepressant drug (R)-(?)-Thiazesim.

Synthesis of α,β-unsaturated aldehydes as potential substrates for bacterial luciferases

Bacterial luciferase catalyzes the monooxygenation of long-chain aldehydes such as tetradecanal to the corresponding acid accompanied by light emission with a maximum at 490?nm. In this study even numbered aldehydes with eight, ten, twelve and fourteen carbon atoms were compared with analogs having a double bond at the α,β-position. These α,β-unsaturated aldehydes were synthesized in three steps and were examined as potential substrates in vitro. The luciferase of Photobacterium leiognathi was found to convert these analogs and showed a reduced but significant bioluminescence activity compared to tetradecanal. This study showed the trend that aldehydes, both saturated and unsaturated, with longer chain lengths had higher activity in terms of bioluminescence than shorter chain lengths. The maximal light intensity of (E)-tetradec-2-enal was approximately half with luciferase of P. leiognathi, compared to tetradecanal. Luciferases of Vibrio harveyi and Aliivibrio fisheri accepted these newly synthesized substrates but light emission dropped drastically compared to saturated aldehydes. The onset and the decay rate of bioluminescence were much slower, when using unsaturated substrates, indicating a kinetic effect. As a result the duration of the light emission is doubled. These results suggest that the substrate scope of bacterial luciferases is broader than previously reported.